Neurocritical Care News

Reata Pharmaceuticals Inc. announced the FDA does not plan to hold an advisory committee meeting to discuss the company’s new drug application for an investigational therapeutic to treat Friedreich’s ataxia.

MediCane Health Inc. announced recruitment of the first patient for its phase 2a study designed to assess the effects of cannabis oil in adults with probable Alzheimer’s disease who have limited or no response to antipsychotic medication.

Empyrean Neuroscience Inc. has announced its launch as a genetic engineering company dedicated to developing fungi- and plant-based therapeutics for the treatment of neuropsychiatric and neurologic disorders.

The FDA has granted breakthrough device designation to neurotechnology company Axoft for its brain-machine interface to treat long-term neurological disorders.

Biotech firm SynaptixBio has entered into a licensing agreement with the Children’s Hospital of Philadelphia, also known as CHOP, to develop a treatment for TUBB4a leukodystrophy, a rare and fatal neurodegenerative disorder.

Erenumab was not effective in reducing pain intensity in patients with trigeminal neuralgia, researchers reported in Lancet Neurology.

Those who survive 30 days of SARS-CoV-2 infection have an increased risk for neurological disorders after 1 year compared with those who were not infected, according to a report in Nature Medicine.

A patient’s age, severity of symptoms, number of previous concussions and family history of psychiatric disorders were associated with a need for additional care before student athletes with concussion could return to play.

A Tulane University neurosurgeon is among the first to perform a procedure with Minnetronix Medical’s MindsEye expandable port, a minimally invasive device for surgical treatment of stroke, cancer and other neurological conditions.

Antidepressant use in pregnancy was not associated with neurodevelopmental disorders in offspring, according to a cohort study published in JAMA Internal Medicine.